<i>In-vitro</i> Cytotoxicity and Antioxidant Studies of <i>Elaeocarpus serratus</i>
AbstractThe pet-ether soluble fraction (PEF), Carbon tetrachloride soluble fraction (CTSF) and Chloroform soluble
fraction (CFSF) of the methanolic extract of stem bark of Elaeocarpus serratus were investigated for
cytotoxic activity using brine shrimp lethality bioassay .The methanolic extract was also evaluated for possible
antioxidant activity using nitric oxide scavenging activity and reducing power assays. In Elaeocarpus serratus,
the LC50 value were found to be 14.94, 0.831 & 3.288 μg/mL in pet-ether soluble fraction (PEF), Carbon
tetrachloride soluble fraction (CTSF) and Chloroform soluble fraction (CFSF) of the methanolic extract
respectively. The extract showed significant antioxidant activity in nitric oxide scavenging activity and
reducing power assay. In nitric oxide scavenging activity, the IC50 value of Elaeocarpus serratus extract was
89.325μg/mL while the IC50 value of ascorbic acid was 47.684μg/mL. It was found that scavenging of nitric
oxide by the extract was concentration dependent.
Key words: Elaeocarpus serratus; Cytotoxicity; Antioxidant; Reducing power.
Stamford Journal of Pharmaceutical Sciences Vol.2(2) 2009: 86-90
Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.